ClinicalTrials.gg
CompletedNCT04468971RESOLVEUpdated Mar 10, 2022

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

A Phase 1 interventional study of CK0802 and Placebo in COVID19 and ARDS, sponsored by Cellenkos, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-10.

Sponsored by Cellenkos, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
856th of 1,321
45 · median 91
Started
2020
with 817 others
Phase 1
178 of 1,859
10 open now
Registered
514th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 856th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 178 in phase 1, and was the 514th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.

03

Conditions studied

  • COVID19
  • ARDS

Browse trials for

Keywords

  • COVID19
  • ARDS
  • CK0802
  • T regulatory cells
  • cord blood
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented to have an RT-PCR-based diagnosis of SARS-CoV-2 infection by RT-PCR
  • Moderate-to-severe ARDS as defined by the Berlin Criteria: ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of 200 mm Hg or less assessed with a positive end-expiratory pressure (PEEP) of >5 cm H2O.
  • Intubated for less than 120 hours
  • Age ≥18 years
  • Ability to provide or duly appointment health care proxy with the authority to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  1. In the opinion of the investigator, unlikely to survive for >48 hours from screening.
  2. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study.
  3. Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV).
  4. Females who are pregnant.
  5. Patients with active bacteremia at start of therapy enrollment or concurrently active moderate to severe other infectious which in the opinion of the investigator may possibly affect the safety of CK0802 treatment.
  6. Patients who have been intubated for more than 120 hours.
  7. Known to DMSO or to porcine or bovine protein.
  8. Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of CK0802 treatment.
  9. High dose .
  10. Receiving an cellular therapy agent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    Excipient

    Drug: Placebo

  • Experimental
    Arm 2

    CK0802: 1x10\^8 cells

    Biological: CK0802

  • Experimental
    Arm 3

    CK0802: 3x10\^8 cells

    Biological: CK0802

Interventions

  • BiologicalCK0802

    Cryopreserved, off the shelf, cord blood derived T regulatory cells

  • DrugPlacebo

    Expicient

06

What researchers measure

Primary outcomes

  1. Regimen related ≥ grade 3 toxicity within 48 hours of first infusion

    Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)

    Time frame: 48 hours

  2. 28-day treatment success, defined as S28

    Alive and not intubated 28 days after the date of first infusion

    Time frame: 28 days

Secondary outcomes

  1. Time to extubation

    Time to extubation

    Time frame: 28 days

  2. Oxygenation improvement

    Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11

    Time frame: 11 days

  3. Ventilator free days

    Ventilator free days measured at day 28

    Time frame: 28 days

  4. Organ failure free days

    Organ failure free days measured at day 28

    Time frame: 28 days

  5. ICU free days

    ICU free days measured at day 28

    Time frame: 28 days

  6. All-cause mortality

    All-cause mortality at day 28

    Time frame: 28 days

07

Study locations

5 sites
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Columbia University
    New York, New York 10027, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Baylor College of Medicine, St Luke's Hospital
    Houston, Texas 77005, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Oct 2021, 12 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 12 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 13, 2020
StartActual
Sep 29, 2020
Primary completionActual
Oct 22, 2021
CompletionActual
Oct 22, 2021
Last update
Mar 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04468971
Lead sponsor
Cellenkos, Inc.
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Sep 29, 2020
Primary completion
Oct 22, 2021
Completion
Oct 22, 2021
Last update
Mar 10, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CK-0802

Start the discussion